Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Extended-Release Tolterodine: Results From the Overactive Bladder Innovative Therapy Trial

Abstract

This multicenter, randomized trial demonstrates that percutaneous tibial nerve stimulation is safe with statistically significant improvements in patient assessment of overactive bladder symptoms, and with objective effectiveness comparable to that of pharmacotherapy. Percutaneous tibial nerve stimulation may be considered a clinically significant alternative therapy for overactive bladder.

Role of percutaneous posterior tibial nerve stimulation either alone or combined with an anticholinergic agent in treating patients with overactive bladder

“…[13] More than 30 studies regarding PTNS have been published. The earliest ones are case series or single-arm efficacy studies, [14][15][16] three are randomized, controlled trials, [9,17,18] and two are long-term follow-up studies of patients who were responders in the overactive bladder innovative therapy (OrBIT) and sham effectiveness in the treatment of overactive bladder symptoms (SUmiT) trials. [19,20] Over half of the patients receiving PTNS therapy in the SUmiT trial, a randomized, double-blinded, sham controlled study, reported moderate or marked improvement in bladder symptoms (54.5% in PTNS patients vs. 20.9% in sham, p<0.001).…”

“…[8] Some randomized controlled studies compared PTNS and anticholinergic drugs (ACDs). [9,10] This study aimed to investigate efficacy and safety of PTNS alone or together with an anticholinergic agent in patients who were diagnosed with OAB and did not respond sufficiently to previous conservative treatment options.…”

Managing overactive bladder in primary care

“…PTNS has been shown to be a safe and effective treatment option, with objective outcome comparable to that of pharmacotherapy. 20 A recent systematic review and meta-analysis reported a pooled subjective success rate of 61.4% and an objective success rate of 60.6%. 21 …”

Non-neuropathic bladder dysfunctions, and treatment approaches

“…(52) bu yöntem ile hastalarının %54,5'inde (plasebo grupta %20.9) semptomlarda orta veya önemli ölçüde iyileşme saptamış.…”